[go: up one dir, main page]

WO2019209217A3 - Modified release formulations of flurbiprofen - Google Patents

Modified release formulations of flurbiprofen Download PDF

Info

Publication number
WO2019209217A3
WO2019209217A3 PCT/TR2018/050846 TR2018050846W WO2019209217A3 WO 2019209217 A3 WO2019209217 A3 WO 2019209217A3 TR 2018050846 W TR2018050846 W TR 2018050846W WO 2019209217 A3 WO2019209217 A3 WO 2019209217A3
Authority
WO
WIPO (PCT)
Prior art keywords
flurbiprofen
release formulations
modified release
release phase
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/050846
Other languages
French (fr)
Other versions
WO2019209217A2 (en
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Kerim AKKAYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority to EP18916470.0A priority Critical patent/EP3727365A4/en
Publication of WO2019209217A2 publication Critical patent/WO2019209217A2/en
Publication of WO2019209217A3 publication Critical patent/WO2019209217A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical formulations of flurbiprofen or a pharmaceutically acceptable salt thereof comprising an immediate release phase and a sustained release phase.
PCT/TR2018/050846 2017-12-21 2018-12-20 Modified release formulations of flurbiprofen Ceased WO2019209217A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18916470.0A EP3727365A4 (en) 2017-12-21 2018-12-20 MODIFIED RELEASE FORMULATIONS BY FLURBIPROFEN

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/21036 2017-12-21
TR2017/21036A TR201721036A2 (en) 2017-12-21 2017-12-21 MODULATED EMISSION FORMULATIONS OF FLURBIPROPHEN

Publications (2)

Publication Number Publication Date
WO2019209217A2 WO2019209217A2 (en) 2019-10-31
WO2019209217A3 true WO2019209217A3 (en) 2020-01-23

Family

ID=67901210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050846 Ceased WO2019209217A2 (en) 2017-12-21 2018-12-20 Modified release formulations of flurbiprofen

Country Status (3)

Country Link
EP (1) EP3727365A4 (en)
TR (1) TR201721036A2 (en)
WO (1) WO2019209217A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12343340B2 (en) 2020-12-31 2025-07-01 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain
EP4536220A1 (en) * 2022-06-13 2025-04-16 Soin Therapeutics LLC Methods of using low dose naltrexone to treat chronic pain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556638A (en) * 1991-12-05 1996-09-17 Alfatec Pharma Gmbh Flurbiprofen-containing immediate-effect medicament and its use
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US8211465B2 (en) * 2007-08-15 2012-07-03 Mcneil-Ppc, Inc. Immediate release and sustained release ibuprofen dosing regimen
WO2016063055A1 (en) * 2014-10-21 2016-04-28 Reckitt Benckiser Llc Pharmaceutical capsule containing at least two tablets

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140183C2 (en) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retard form for a medicine containing flurbiprofen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556638A (en) * 1991-12-05 1996-09-17 Alfatec Pharma Gmbh Flurbiprofen-containing immediate-effect medicament and its use
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US8211465B2 (en) * 2007-08-15 2012-07-03 Mcneil-Ppc, Inc. Immediate release and sustained release ibuprofen dosing regimen
WO2016063055A1 (en) * 2014-10-21 2016-04-28 Reckitt Benckiser Llc Pharmaceutical capsule containing at least two tablets

Also Published As

Publication number Publication date
TR201721036A2 (en) 2019-07-22
EP3727365A2 (en) 2020-10-28
EP3727365A4 (en) 2021-06-16
WO2019209217A2 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
CL2017003320A1 (en) Pharmaceutical formulations containing tenofovir and emtricitabine
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
AU2012280198A8 (en) Darunavir combination formulations
EP3613419A4 (en) Pharmaceutical composition containing indirubin derivative as active ingredient
ZA202103228B (en) Crystal forms of an alk2 inhibitor
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
WO2020009675A3 (en) Solid oral pharmaceutical compositions of linagliptin
WO2019209217A3 (en) Modified release formulations of flurbiprofen
EA201991286A1 (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN
PH12021551396A1 (en) Active ester derivatives of testosterone, compositions and uses thereof
PH12018501758A1 (en) Oritavancin formulations
SMT202500145T1 (en) Co-crystal of ketoprofen and its preparation, pharmaceutical compositions comprising the same and uses thereof
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
WO2019190436A3 (en) The combination comprising adapalene and benzoyl peroxide
AU2018286535A1 (en) Delayed sustained release pharmaceutical compositions
EP3612185A4 (en) Pharmaceutical compositions comprising poh derivatives and methods of use
EP3687539A4 (en) Stable pharmaceutical compositions of dalfampridine
WO2019221684A3 (en) The bilayer tablet formulation of fesoterodine
WO2019203747A3 (en) The pharmaceutical combination comprising raloxifene and at least one antipsychotic agent
PH12016502527B1 (en) Stabilized desmopressin
TR201721065A2 (en) Lyophilized pharmaceutical formulations comprising dexmedetomidine
HK40075060A (en) Pharmaceutical formulations of tenofovir alafenamide
WO2020018034A3 (en) Oral pharmaceutical compositions comprising dpp-4 inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18916470

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018916470

Country of ref document: EP

Effective date: 20200721

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18916470

Country of ref document: EP

Kind code of ref document: A2